Ivabradine Viatris (Ivabradine Oxalate)

Ivabradine works by selectively inhibiting the funny (If) current in the sino‑atrial node, the pacemaker of the heart. This inhibition slows the spontaneous depolarisation of cardiac cells, resulting in a lower heart rate without compromising contractile strength or blood pressure.

The appropriate dose of Ivabradine Viatris is determined by the prescribing clinician based on the patient’s heart‑rate, clinical condition and response to therapy. Dosage adjustments may be required during treatment, and patients should follow the prescriber’s instructions exactly.

Safety data for ivabradine during pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Ivabradine Viatris, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Both ivabradine and beta‑blockers lower heart rate, but ivabradine does so by directly inhibiting the If current without affecting beta‑adrenergic receptors. This means it does not influence blood pressure or contractility, making it a useful adjunct when beta‑blockers alone are insufficient or not tolerated.

Ivabradine tablets should be stored at ambient temperature, below 25 °C, in the original container. Keep them away from moisture and direct light, and ensure the packaging remains tightly closed until use.

Ivabradine Viatris is taken orally, usually with a glass of water. The tablets are swallowed whole and should be taken with or without food as directed by the prescriber. Consistency in timing each dose helps maintain stable blood‑level concentrations.

The most serious risks include symptomatic bradycardia, atrial fibrillation, severe visual disturbances, and rare allergic reactions. Patients should report any episodes of dizziness, fainting, palpitations, or visual changes to their healthcare provider promptly.

Ivabradine is contraindicated in patients with severe hepatic impairment, sick sinus syndrome, acute myocardial infarction, unstable angina, or those taking strong CYP3A4 inhibitors. It should also be avoided in individuals with a resting heart rate below the threshold set by the prescriber.